Log in to search using one of your social media accounts:


Roche ’s OCREVUS (ocrelizumab) approved in the European Union for relapsing forms of multiple sclerosis and primary progressive multiple sclerosis

Roche announced today that the European Commission (EC) has granted marketing authorisation for OCREVUS ® (ocrelizumab) for patients with active relapsing forms of multiple sclerosis defined by clinical or imaging features and for patients with early primary progressive multiple sclerosis in terms of disease duration and level of disability, and with imaging features characteristic of inflammatory ac tivity.
Source: Roche Media News - Category: Pharmaceuticals Source Type: news

Related Links:

Conclusions from the literature are that larger studies are needed to confirm the exciting results from initial investigations before current trends in diffusion imaging can be translated to the neurology clinic. Also, for a comprehensive understanding of pathological processes, it is essential to take a multiple‐level approach, in which information at the micro‐, meso‐ and macroscopic scales is fully integrated. Diffusion in multiple sclerosis (MS) can provide information about the microstructure, but this might not be sufficient to explain clinical disability: the functional system impairment might emerge only whe...
Source: NMR in Biomedicine - Category: Radiology Authors: Tags: SPECIAL ISSUE REVIEW ARTICLE Source Type: research
Multiple sclerosis —MS. These two letters can change lives in an instant for young people starting out in their careers and family life. MS is hard to define, hard to treat, and hard to take. Yet over the past two decades, treatment has changed radically, from none to over a dozen disease modifying drugs that can re duce attack rate and mitigate disability. The 2017 revisions of the multiple sclerosis diagnostic criteria1 provide an opportunity for reflection.
Source: Lancet Neurology - Category: Neurology Authors: Tags: In Context Source Type: research
Abstract BackgroundMultiple sclerosis (MS) is most frequent in Caucasian populations. However, studies of MS in other ethnic groups may offer unique insights into genetic and environmental influences on disease, and data on long‐term outcomes in these patients is limited. We have investigated clinical features and time to disability milestones in ethnic minority (EM) patients with MS in a UK population and made comparisons to a Caucasian cohort from the same region. Methods1949 MS patients (1866 Caucasian, 83 EM) were identified from a regional disease registry. Cox proportional hazards regression was used to analyse tim...
Source: European Journal of Neurology - Category: Neurology Authors: Tags: Short Communications Source Type: research
Interferon β-1a and β-1b for patients with multiple sclerosis: updates to current knowledge. Expert Rev Clin Immunol. 2018 Jan 10;: Authors: Zettl UK, Hecker M, Aktas O, Wagner T, Rommer PS Abstract INTRODUCTION: Although multiple sclerosis (MS) remains incurable, interferon beta (IFNβ) has been at the forefront of treatment for many years. Different formulations of IFNβ allow for different levels of exposure: low-dose/frequency with some agents, and high-dose/frequency with others. Areas covered: This review article discusses existing and emerging efficacy and safety data for IFN&b...
Source: Expert Review of Clinical Immunology - Category: Allergy & Immunology Tags: Expert Rev Clin Immunol Source Type: research
This article is protected by copyright. All rights reserved. Myelin mutant taiep rats had shorter dendrites and fewer dendritic boutons respect to normal Sprague‐Dawley rats in the CA1, but not in CA3 field of the hippocampus. The changes in the dendrites did not affect espacial memory measured through water Morris test in taiep rats.
Source: Synapse - Category: Neurology Authors: Tags: Research Article Source Type: research
Conclusions: Our results showed that alemtuzumab can be considered as more effective and less costly than the other treatment alternatives. There is a substantial potential cost saving if more patients start on the more effective and less costly treatment alternatives. PMID: 29317954 [PubMed]
Source: Clin Med Res - Category: Research Authors: Tags: J Clin Med Res Source Type: research
CONCLUSION: Maximum aerobic capacity was severely reduced in persons with multiple sclerosis-related fatigue. This partly explains the limited physical functioning and restrictions in participation and autonomy indoors, outdoors and in social life and relationships in these persons. PMID: 29313870 [PubMed - as supplied by publisher]
Source: Journal of Rehabilitation Medicine - Category: Rehabilitation Tags: J Rehabil Med Source Type: research
Conclusion: A variety of inflammatory, infective, demyelinating, and autoimmune disorders present with acute transverse myelopathy. Early institution of methylprednisolone reduces the disability in these patients.
Source: Neurology India - Category: Neurology Authors: Source Type: research
BACKGROUND AND PURPOSE: The spatial correlation between WM and cortical GM disease in multiple sclerosis is controversial and has not been previously assessed with perfusion MR imaging. We sought to determine the nature of association between lobar WM, cortical GM, volume and perfusion. MATERIALS AND METHODS: Nineteen individuals with secondary-progressive multiple sclerosis, 19 with relapsing-remitting multiple sclerosis, and 19 age-matched healthy controls were recruited. Quantitative MR perfusion imaging was used to derive CBF, CBV, and MTT within cortical GM, WM, and T2-hyperintense lesions. A 2-step multivariate line...
Source: American Journal of Neuroradiology - Category: Radiology Authors: Tags: ADULT BRAIN Source Type: research
FINDINGSA study by UCLA researchers reveals the cellular basis for how the hormone estrogen protects against damage to the central nervous system in women with multiple sclerosis, or MS. The researchers found that estrogen treatment exerts positive effects on two types of cells during disease — immune cells in the brain as well as cells called oligodendrocytes.BACKGROUNDUCLADr. Rhonda VoskuhlMultiple sclerosis is a chronic autoimmune, neurodegenerative disease marked by visual impairment, weakness and sensory loss, as well as cognitive decline. These symptoms emerge when inflammatory immune cells destroy the myelin s...
Source: UCLA Newsroom: Health Sciences - Category: Universities & Medical Training Source Type: news
More News: Disability | Marketing | Multiple Sclerosis | Pharmaceuticals